Drug Trial Radar · NCT07404137
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Feb 16, 2026
Primary completion
Apr 2, 2026
Study completion Apr 2, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the concentrations of zibotentan and dapagliflozin in blood when given with and without food in healthy participants.
Conditions
- Healthy Participants
Interventions
Zibotentan/Dapagliflozin FDCDrug
Zibotentan/Dapagliflozin FDC will be administered as an oral tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under concentration-time curve from time 0 to infinity (AUCinf)Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods
- Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods
- Maximum observed drug concentration (Cmax)Time frame: At predefined intervals from Day 1 to Day 4 for both treatment periods
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.